Active Influenza Vaccine Safety Surveillance
Authors:
- Jeffrey S. BrownJBJeffrey S. Brown
- Kristen M. MooreKMKristen M. Moore
- M Miles BraunMBM Miles Braun
- Najat ZiyadehNZNajat Ziyadeh
- K Arnold ChanKCK Arnold Chan
- Grace M. LeeGLGrace M. Lee
- Martin KulldorffMKMartin Kulldorff
- Alexander M. WalkerAWAlexander M. Walker
- Richard PlattRPRichard Platt
- 1 December 2009
- journal article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 47 (12) , 1251-1257
Abstract
Background: Rapid safety assessment of novel vaccines, especially those targeted against pandemic influenza, is a public health priority. Objectives: Assess the feasibility of using healthcare claims data to rapidly detect influenza vaccine adverse events using sequential analytic methods. Research Design: Retrospective pilot study simulating prospective surveillance using 6 cumulative monthly administrative claims data extracts. The first included encounters occurring in October; each subsequent extract included an additional month of encounters. Ten adverse events were evaluated, comparing postvaccination rates during the 2006–2007 influenza season to those expected based on rates observed in the prior season. Subjects: Members of a large, multistate health insurer who had a claim for influenza vaccination during the 2005–2006 or 2006–2007 influenza seasons. Measures: The completeness of monthly claims extracts. Results: Most vaccinations and outcomes were identified early in the 2006–2007 season; about 50% of vaccinations and short latency events were identified in the second monthly data extract, which would typically become available by mid-December, and 80% of vaccinations and events were identified in the third extract. With respect to overall claims lag, approximately 90% of vaccinations and events were identified within 1 to 2 months after vaccination, regardless of vaccination month. Conclusions: This study suggests that administrative claims data might contribute to same season influenza vaccine safety surveillance in large, defined populations, especially during a threat of pandemic influenza. Based on our previous work, we believe this method could be applied to multiple health plans’ data to monitor a large portion of the US population.Keywords
This publication has 19 references indexed in Scilit:
- A distributed research network model for post‐marketing safety studies: the Meningococcal Vaccine StudyPharmacoepidemiology and Drug Safety, 2008
- Early detection of adverse drug events within population‐based health networks: application of sequential testing methodsPharmacoepidemiology and Drug Safety, 2007
- Real-Time Vaccine Safety Surveillance for the Early Detection of Adverse EventsMedical Care, 2007
- Guillain-Barré Syndrome After Influenza Vaccination in AdultsArchives of internal medicine (1960), 2006
- Active Surveillance of Vaccine SafetyEpidemiology, 2005
- Guillain-Barré Syndrome Following Influenza VaccinationJAMA, 2004
- Safety of the Trivalent Inactivated Influenza Vaccine Among ChildrenArchives of Pediatrics & Adolescent Medicine, 2004
- The Vaccine Safety Datalink projectPharmacoepidemiology and Drug Safety, 2001
- Postmarketing Surveillance and Adverse Drug ReactionsJAMA, 1999
- Reporting of adverse events to MedWatchAmerican Journal of Health-System Pharmacy, 1995